Algeta ASA : Algeta schedules fourth quarter 2011 results presentation, webcast and conference call

Oslo, Norway, 1 February 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its fourth quarter and full year 2011 results on Thursday, 9 February 2012. A presentation by Algeta's senior management team to investors, analysts and the press will take place in Oslo at 10:00 CET.

The presentation will also be webcast live and can be accessed at www.algeta.com/webcast where questions can also be submitted during the presentation.

The presentation will take place at 10:00 CET at:

Shippingklubben
Haakon VIIs gate 1
0161 Oslo
Norway.

Algeta's senior management will also host an international conference call at 14:30 CET/08:30 Eastern Time (US) (details below).

To participate in the conference call, please dial the appropriate number below five minutes prior to the call:

USA: +1 866 5088 015
UK: +44 203 147 4601
Norway: +47 21 01 09 30
Sweden: +46 850 559 840
Switzerland: +41 225 802 964
For other countries, please see the attached list of access numbers.

Participant pin code: 537060#

To access the replay, please dial:

SE: +46 (0)8 506 269 49
UK: +44 207 750 99 28
US: 18663056292
Conference reference: 266998#

A replay of the conference call will also be available at www.algeta.com.

The results report and the presentation will be available at www.algeta.com in the Investors section from 07:00 CET.

###

For further information, please contact

About Algeta

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.

Algeta's lead product Alpharadin (radium-223 chloride) is in development as a potential new treatment for cancer patients with bone metastases. It is in pre-registration for castration-resistant prostate cancer (CRPC) patients with bone metastases, and filings are expected mid 2012 in the USA and Europe; Alpharadin has Fast Track designation for this indication in the USA.

Alpharadin is also under clinical investigation in breast cancer patients with bone metastases and in combination with docetaxel chemotherapy in CPRC patients with bone metastases.

Alpharadin is being developed and will be commercialized, pending approval, under a global agreement with Bayer Pharma AG.

Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs), which are based on conjugating the alpha-emitter thorium-227 to targeting molecules, as a basis of a future pipeline of tumor-targeting alpha-pharmaceutical candidates.

The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statements
This news release contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. Such forward-looking statements reflect our current views and are based on the information currently available to Algeta. Algeta cannot give any assurance to the correctness of such statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials, collaborations with other companies in the development of targeting molecules and alpha particle payloads, risks associated with technological development, growth management, general economic and business conditions and the pricing environment, the impact of competition, the ability to successfully commercialize Alpharadin and our other products, the risk that research & development will not yield new products that achieve commercial success, manufacturing capacity, the risk of non-approval of patents not yet granted, risks in obtaining regulatory approvals for Alpharadin and our other products and difficulties of obtaining relevant governmental approvals for new products, and the other risks and uncertainties described in our annual report.

Partner Area